N/A N=14 Chronic Kidney Disease Among Frail Elderly
Chronic Kidney Disease
Primary: Mortality — 0; 0 percentage of mortality
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=32 Exercise Intolerance in Renal Failure
Kidney Failure, Chronic
Primary: Change in Resting Muscle Sympathetic Nerve Activity (MSNA) — -7.5; 3.2 bursts/minute
Phase 2 N=11 Mitochondria and Chronic Kidney Disease
Hemodialysis-Induced Symptom · Mitochondrial Diseases
Primary: Phosphocreatine (PCR) Recovery Time After Knee Extension Assessed by 31 Phosphorus Magnetic Resonance Spectroscopy (31P-MRS) — 60.59; 62.66 seconds
Phase 3 N=289 Ferric Citrate for the Prevention of Renal Failure in Adults With Advanced Chronic Kidney Disease
Anemia, Iron Deficiency · Hyperphosphatemia · Renal Insufficiency, Chronic
Primary: Number of Participants Achieving a Composite Endpoint of Initiation of Maintenance Dialysis or All-cause Mortality — 35; 46 Participants — p=.1602
N/A N=73 Kidney Response to Sepsis Affects Angiogenic Balance and Likelihood of CCI and PICS
Sepsis
Primary: Delta Curve Between Calculated GFR and GFR Measured by Iohexol at Baseline — 91.5; 88.3; 93.6; 90.0 ml/min/1.73m2 — p=<0.05
N/A N=125 Home-base Kidney Care in Zuni Indians
Chronic Kidney Disease
Primary: Patient Activation Measure (PAM) -13 Item Questionnaire — 9.1; -1.4 points — p=0.01
N/A N=186 Home-Based Kidney Care in Native American's of New Mexico (HBKC)
Chronic Kidney Diseases
Primary: The Patient Activation Measure (PAM) — 60.8; 61.5; 1.73; 3.44 score on a scale
N/A N=781 Chronic Kidney Disease (CKD) Guideline Adherence - A Quality Improvement Study
Chronic Renal Insufficiency
Primary: PTH (Parathyroid Hormone) Adherence — 0.23; 0.28 probability of having a PTH measured — p=0.04
N/A N=4,003 Personalized Recommendations for Acute Kidney Injury (AKI) Care
Acute Kidney Injury
Primary: Composite Outcome Showing the Percentage of Participants With Any One of the Following: Progression of AKI, Inpatient Dialysis, or Inpatient Death — 369; 395…
Phase 2 N=60 Metformin in Kidney Disease
Chronic Kidney Disease · Cardiovascular Disease · Metabolic Syndrome
Primary: Change is Leptin to Adiponectin Ratio (LAR) — 2.2; 1.3; 1.3; 1.4 ng/micrograms
Phase 2 N=52 Mannitol - Potential Role in Hemodialysis Initiation for Reduction of Intra-dialytic Hypotension
Intra-dialytic Hypotension
Primary: Efficacy of Mannitol Administration in Reducing the Frequency of Intra-dialytic Hypotension (Decline in Systolic Blood Pressure) During the First Three Hemodialysis…
N/A N=64,882 Epidemiology of Acute Kidney Injury in England - 1998 to 2013
Acute Kidney Injury
Primary: Secular Trends in the Mortality After Acute Kidney Injury From 1998 to 2013 — 1296; 3763; 19793 participants
Phase 2 N=24 Nutrition, Inflammation and Insulin Resistance in End Stage Renal Disease-Aim 2
ESRD
Primary: Change in Leucine Disposal Rate (LDR) — -0.011; 0.005; 0.001 mg/kg/min — p=0.37
Phase 4 N=267 Preop Digifab in CABG to Reduce Ouabain Levels and Prevent AKI
Acute Kidney Injury
Primary: Renal Function — .46; .75; 4.26; 2.80 mL/min/1.73m^2 — p=>0.05
Phase 3 N=188 Effectiveness of Ultrafiltration in Treating People With Acute Decompensated Heart Failure and Cardiorenal Syndrome (The CARRESS Study)
Heart Failure
Primary: Change in Serum Creatinine — -0.04; 0.23 mg/dL
Phase 4 N=57 Kidney Damage in Patients With Moderate Fall in eGFR
Coronary Artery Stenosis
Primary: Impact on the Trajectory of Serum and Urinary Neutrophil Gelatinase-associated Lipocalin (NGAL) Following Administration — -27.76; -11.11; -11.84; -8.23 ng/mL
Phase 1 N=11 Safety, Tolerability, and Pharmacokinetics of KBP-5074 Following Oral Administration in Chronic Kidney Disease
Chronic Kidney Disease
Primary: Number of Participants With Treatment-related Adverse Events — 0 Participants
N/A N=23 High Water Intake to Slow Progression of Polycystic Kidney Disease
Kidney, Polycystic, Autosomal Dominant
Primary: Change in Urine cAMP Concentration and Urine Osmolality (UOsm) — -2.6; -2.0 fold change in cAMP/UOsm (umol/UOsm)
Phase 2 N=36 Losartan to Reverse Sickle Nephropathy
Nephropathy · Sickle Cell Anemia
Primary: Categorical Change in Urinary Albumin-to-creatinine Ratio (UACR) From Baseline — 1; 7; 5 Participants
Phase 3 N=149 Alkali Therapy in Chronic Kidney Disease
Chronic Kidney Disease · Metabolic Acidosis
Primary: Sit to Stand to Sit Speed: Time Taken to Sit to Stand to Sit 10 Times — 23.8; 22.9 seconds
N/A N=96 The Effect of Loop Diuretics on Severity and Outcome of Acute Kidney Injury
Acute Kidney Failure
Primary: Progression to Stage 3 AKI — 23 Participants
N/A N=4 Phosphodiesterase Type 5 Inhibition to Improve Endothelial Function and Vascular Remodeling in Chronic Kidney Disease and End Stage Renal Disease Patients Requiring New Arteriovenous Fistula
Improve Endothelial Function and Decrease Vascular Stenosis
Primary: Change in Baseline and 2 Week FMD/VP Measurements Between Sildenafil Group and Placebo Group — 10.8; 8.6 Change in FMD%
N/A N=10,252 IMPROVE AKI Cluster-Randomized Trial
Acute Kidney Injury
Primary: Acute Kidney Injury — 110; 190; 122; 88 Participants
N/A N=350 Safe Kidney Care Cohort Study
Chronic Kidney Disease
Primary: The Discrete Incidence of Any of the Chronic Kidney Disease Patient Safety Indicators (CKD-PSIs) Endorsed by the Consensus Expert Panel — 108.7; 100.6; 38.3; 41.2 events…
N/A N=206 HIV and Kidney Function Study
HIV Infections · AIDS
Primary: Performance of Glomerular Filtration Rate (GFR) Estimating Equations — 10.9; 5.4; 4.3; 6.4 mL/min per 1.73 m^2
N/A N=6,295 Chronic Kidney Disease Clinical Decision Support
Chronic Kidney Diseases · Hypertension · Diabetes
Primary: Number of Participants With CKD Diagnosis — 417; 389 Participants — p=.21
Phase 3 N=1,124 Acute Renal Failure Trial Network (ATN) Study
Acute Renal Failure
Primary: 60-day All-cause Mortality — 302; 289 participants — p=0.47
N/A N=15,724 Intensive Monitoring of Renal Function
Intensive Monitoring of Renal Function · Acute Kidney Injury
Primary: Detection of Acute Kidney Injury (AKI) — 1.22; 1.22; 1.11; 1.11 Odds Ratio
N/A N=18 Renal Perfusion, Filtration and Oxygenation During Cardiopulmonary Bypass (CPB)
Complication of Extracorporeal Circulation · Renal Impairment
Primary: Renal Blood Flow (RBF) — 554; 524; 564; 558 ml per minute per 1.73 m2 body surface — p=0.638
Phase 3 N=88 Erythropoietin (EPO) and Ischemia-reperfusion After Kidney Transplantation
Kidney Transplantation
Primary: Kidney Graft Function by Estimated Glomerular Filtration Rate (eGFR) — 47; 46 ml/min — p=<0.05